Xtandi (enzalutamide)

News alerts, weekly reports and conference planners

Company:

Astellas, Pfizer

Drug class:

Androgen receptor inhibitor

Related drugs:

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide Sensitive: A1 - Approval enzalutamide Sensitive : A1	enzalutamide Sensitive: A1 - Approval enzalutamide Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1	talazoparib + enzalutamide Sensitive: A1 - Approval talazoparib + enzalutamide Sensitive : A1
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	enzalutamide Resistant: A2 - Guideline enzalutamide Resistant : A2	enzalutamide Resistant: A2 - Guideline enzalutamide Resistant : A2
AR amplification	Prostate Cancer	AR amplification	Prostate Cancer	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B
TP53 deletion	Prostate Cancer	TP53 deletion	Prostate Cancer	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B
RB1 deletion	Prostate Cancer	RB1 deletion	Prostate Cancer	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B
BRCA2 deletion	Prostate Cancer	BRCA2 deletion	Prostate Cancer	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B
CD8 expression	Prostate Cancer	CD8 expression	Prostate Cancer	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B
PD-L1 overexpression	Prostate Cancer	PD-L1 overexpression	Prostate Cancer	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B
AR wild-type	Prostate Cancer	AR wild-type	Prostate Cancer	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	talazoparib + enzalutamide Sensitive: B - Late Trials talazoparib + enzalutamide Sensitive : B	talazoparib + enzalutamide Sensitive: B - Late Trials talazoparib + enzalutamide Sensitive : B
AR splice variant 7 negative	Prostate Cancer	AR splice variant 7 negative	Prostate Cancer	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B	enzalutamide Sensitive: B - Late Trials enzalutamide Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2
AR F877L	Prostate Cancer	AR F877L	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
AR F876L	Prostate Cancer	AR F876L	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab + enzalutamide Sensitive: C3 – Early Trials pembrolizumab + enzalutamide Sensitive : C3	pembrolizumab + enzalutamide Sensitive: C3 – Early Trials pembrolizumab + enzalutamide Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
AR expression	Prostate Cancer	AR expression	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
AR overexpression	Prostate Cancer	AR overexpression	Prostate Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
CYP17A1 expression	Prostate Cancer	CYP17A1 expression	Prostate Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
IRF8 expression	Prostate Cancer	IRF8 expression	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
AR-V7 negative	Prostate Cancer	AR-V7 negative	Prostate Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3
AR-V7 overexpression	Prostate Cancer	AR-V7 overexpression	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
Chr del(10)	Prostate Cancer	Chr del(10)	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
TP53 mutation	Prostate Cancer	TP53 mutation	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
MYCN amplification	Prostate Cancer	MYCN amplification	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
CHD1 deletion	Prostate Cancer	CHD1 deletion	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
BRCA2 amplification	Prostate Cancer	BRCA2 amplification	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3

Xtandi (enzalutamide)

Associations
(78)

Associations
(78)

Xtandi (enzalutamide)

Associations(78)

Associations(78)

Associations
(78)

Associations
(78)